Seed first close · Biotech
Laigo Bio raises €11.5m seed to advance targeted therapies
Kurma Partners and Curie Capital co-lead the financing.
Laigo Bio announced an €11.5 million seed round on December 4, 2025, co-led by Kurma Partners and Curie Capital. Participants included Argobio Studio, Angelini Ventures, Eurazeo, Oncode Bridge Fund, ROM Utrecht Region and Cancer Research Horizons.
The Utrecht company will advance oncology programmes towards clinical development and develop candidates for autoimmune disease and graft rejection. Its SureTACs platform targets disease-driving proteins on cell surfaces for selective degradation.
Use of funds
Advance oncology programmes through preclinical development
Develop autoimmune and graft-rejection drug candidates
Funding history
Seed first close · This round€11.5M
TKI-MKB research grantUndisclosed